About AxioMx
AxioMx is a company based in Branford (United States) founded in 2012 by Christopher McLeod was acquired by Abcam in November 2015. AxioMx has raised $4.11 million across 8 funding rounds from investors including Abcam, NIH and HHS. AxioMx operates in a competitive market with competitors including Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
- Headquarter Branford, United States
- Founders Christopher McLeod
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of AxioMx
AxioMx has successfully raised a total of $4.11M across 8 strategic funding rounds. The most recent funding activity was a Grant round of $216 thousand completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AxioMx
AxioMx has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Abcam, NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
|
Locked | Locked | Locked | |
|
VC firm investing in seed & early stage companies in the US
|
Locked | Locked | Locked | |
|
Private investments are made in early and later-stage businesses.
|
Locked | Locked | Locked |
Investor details for AxioMx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AxioMx
Investment portfolio details for AxioMx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AxioMx
Detailed financials for AxioMx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Axiomx Comparisons
Peer comparison for AxioMx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AxioMx
AxioMx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein-based assays are developed for life science research.
|
|
| Locked | Locked | Locked |
A proteomics platform is developed for analyzing the human proteome.
|
|
| Locked | Locked | Locked |
Peptide-based therapeutics are developed for cancers and immune disorders.
|
|
| Locked | Locked | Locked |
Proteomics services are delivered via discovery and targeted platforms.
|
|
| Locked | Locked | Locked |
Digital platform transforming the delivery of biologic medicines
|
|
| Locked | Locked | Locked |
Provider tools to help researchers with protein analysis
|
Detailed competitors of AxioMx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Axiomx
Complete news archive for AxioMx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AxioMx
AxioMx was founded in 2012.
AxioMx is headquartered in Branford, United States. It is registered at Branford, Connecticut, United States.
Christopher McLeod is the current CEO of AxioMx. They have also founded this company.
AxioMx is a funded company, having raised a total of $4.11M across 8 funding rounds to date.
AxioMx was founded in 2012 in Branford, United States, within the biotechnology sector. A platform for recombinant antibody discovery and development services is maintained, featuring phage display libraries, screening, and affinity maturation techniques to shorten antibody development timelines. Services encompass recombinant antibody development, optimization, antigen design, and project planning. The company was acquired by Abcam in 2015.
AxioMx's top competitors include Somalogic, Nautilus Biotechnology and Elektrofi.
AxioMx has 6 investors. Key investors include Abcam, NIH, HHS, Elm Street Ventures, and Connecticut Innovations.